Our Pipeline

We are harnessing the power of data and machine learning to program biology to dramatically improve the human condition in areas such as oncology, immunology, and infectious disease.

Program Target Generating IND-enabling Phase 1 Phase 2 Phase 3 Collaborations
Immunology
GB-0895 TSLP
A purple bar labeled IND-enabling
Generation program TL1A
A purple bar labeled Generating
Generation program IL-13
A purple bar labeled Generating
Infectious Disease
GB-0669 SARS-CoV-2
S2 Domain
An orange bar labeled Phase 1
SARS SARS-CoV-2
RBD Domain
An orange bar labeled IND-enabling
Influenza
An orange bar labeled Generating
Oncology
Generation program
A green bar labeled Generating
 The University of Texas MD
Anderson Cancer Center
Generation program
A green bar labeled Generating
 The University of Texas MD
Anderson Cancer Center
Generation program
A green bar labeled Generating
Generation program
A green bar labeled Generating
Generation program
A green bar labeled Generating
Generation program
A green bar labeled Generating
Undisclosed
Generation program Undisclosed
Generation program Undisclosed
Generation program Undisclosed
Generation program Undisclosed
Generation program Undisclosed
Generation program Undisclosed
Policy on Expanded Access (EA) to Investigational Drugs

Currently, participation in clinical trials is the only way for patients to gain access to Generate:Biomedicines’ investigational therapies. As more clinical data on the safety and efficacy of these investigational therapies become available, we will review and update our policy on Expanded Access.

FDA Guidance on EA